CDKL3 promotes osteosarcoma progression by activating Akt/PKB
Aina He(Guangxi University), Dongxi Xiang(Brigham and Women's Hospital), Hao Wu(Yanbian University of Science and Technology), Songhai Tian(Boston Children's Hospital), Wentao Dai(Shanghai Jiao Tong University), Ting Yuan(Goethe University Frankfurt), Ren Sheng(Northeastern University), Lanjing Ma(Xijing Hospital), Yujing Huang(Fujian Medical University), Min Dong(Boston Children's Hospital), Zexu Li(Universidad del Noreste), Wei Duan(Deakin University), Yonggang Wang(Unknown), Hongtao Li(Xinjiang Medical University), Chunyan Wang(Washington University in St. Louis), Fei Teng(Tongji University), Haijiao Zhang(Oregon Health & Science University), Yueqing Bai(Shanghai Sixth People's Hospital), Liguo Liu(Shanghai Jiao Tong University), Yong Sun(Tongren Hospital), Qingcheng Yang(Shanghai Jiao Tong University), Yaling Wang(Hong Kong Polytechnic University), Junqing Yuan(Shanghai Sixth People's Hospital)
Cited by 18
Related Papers
Small molecules in targeted cancer therapy: advances, challenges, and future perspectives
|Signal Transduction and Targeted Therapy|2021|1.7k
CB-Dock: a web server for cavity detection-guided protein–ligand blind docking
|Acta Pharmacologica Sinica|2019|898
Characterizing a model human gut microbiota composed of members of its two dominant bacterial phyla
|Proceedings of the National Academy of Sciences|2009|758